CAC Croit Corporation

What CAC Croit Corporation does

EPS Corporation (イーピーエス株式会社), founded in 1991 and headquartered in Tokyo, is a full-service Japanese Contract Research Organization (CRO) and a wholly-owned operating subsidiary of EPS Holdings Co., Ltd. The company delivers end-to-end clinical development support — from clinical planning, PMDA consultation support, monitoring (including centralized and risk-based monitoring), data management, statistical analysis, medical writing, eCTD/Gateway regulatory submissions, GCP auditing, pharmacovigilance, post-marketing surveillance, and real-world evidence generation — to pharmaceutical companies, medical device manufacturers, academic medical centers, and regenerative medicine developers primarily in Japan, with extended operations into Taiwan, Korea, and the United States via the EPS Group network.

EPS operates an integrated platform-plus-modules architecture: full-service clinical delivery is augmented by a portfolio of proprietary IT tools (zenflow, Vigilia, SWIFTeS/SWIFTeS Proof, EXSUS, BESTS, QualityLead, Evidence Driver, Voicebook, My治験, easyPRO, EP mobile, ToolBox/eCTDXPress) and embedded third-party technology integrations with Medidata, Veeva, ArisGlobal, CluePoints, AWS, SAS, 4G Clinical, Bioclinica, and Spotfire. Notable technical assets include an AWS-certified safety management package (zenflow), a granted patent for a statistical signal inference model, and a patent-pending AI×RWD methodology for machine learning-based outcome validation. Generative AI capability was formalized company-wide in May 2026 through an AI Basic Policy and full deployment of Microsoft 365 Copilot.

EPS generates revenue through negotiated B2B enterprise contracts with pharmaceutical, medical device, and regenerative medicine clients for project-based clinical development services; pricing is not publicly disclosed. The go-to-market is anchored on direct professional services delivery supplemented by industry conference presence (DIA, BioJapan, Medtec Japan, CPHI Japan), a 10,000+ cumulative participant webinar program, and academic presentations at SAS User Group, CDISC Japan Interchange, and clinical research society forums. The customer base is segmented by vertical rather than company size, and EPS has secured multiple first-in-Japan vendor accreditations (CluePoints RBQM, Medidata Balance RTSM, Medidata myMedidata eCOA) that signal competitive positioning within the Japanese CRO market.

Name

CAC Croit Corporation

Legal name

イーピーエス株式会社 (EPS Corporation)

Website

https://croit.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

EPS Corporation is a Tokyo-based full-service Japanese CRO founded in 1991 and subsidiary of EPS Holdings, delivering end-to-end clinical development, regulatory, pharmacovigilance, and real-world evidence services to pharmaceutical, medical device, academic, and regenerative medicine clients across Japan and East Asia.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Custom Computer Programming Services (541511), Marketing Research and Public Opinion Polling (541910)

SIC

Services-Management Consulting Services (8742), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Contract research services
• Clinical trial management
• Pharmacovigilance services
• Regulatory affairs consulting
• Medical device development

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels5 records

Core offering

EPS Corporation is a Japan-based full-service Contract Research Organization (CRO) providing comprehensive clinical development solutions for pharmaceutical, medical device, IVD, and regenerative medicine companies. It delivers end-to-end services spanning clinical planning, PMDA consultation support, monitoring, decentralized clinical trial (DCT) implementation, risk-based monitoring (RBM/RBQM), data management, statistical analysis, medical writing, eCTD regulatory submissions, pharmacovigilance, and post-marketing surveillance, augmented by a portfolio of proprietary IT tools (zenflow, Vigilia, SWIFTeS, EXSUS, BESTS, Evidence Driver, easyPRO, Voicebook, My治験).

Product overview

EPS Corporation (イーピーエス株式会社) is a full-service CRO (Contract Research Organization) providing comprehensive solutions for pharmaceutical, medical device, and regenerative medicine product development. The company's portfolio operates as an integrated platform-plus-modules architecture with core clinical development services (monitoring, data management, statistical analysis, medical writing, regulatory affairs) supported by proprietary IT tools and third-party technology integrations. Key product categories include: (1) Core Clinical Services - regulatory affairs, clinical monitoring, data management, statistical analysis, pharmacovigilance; (2) Patient Engagement Solutions - Voicebook for patient participation, My治験 DCT platform, Consent support videos (コンサポ); (3) Proprietary IT Tools - zenflow (safety information management), Vigilia (post-market surveillance), EXSUS/BESTS (statistical analysis), SWIFTeS (document management), Spotfire services; (4) RBQM Solutions - CluePoints for risk-based quality management; and (5) Evidence Generation - Evidence Driver for real-world data analysis. The company integrates with major platforms including Medidata, Veeva, SAS, ArisGlobal, and AWS, while employing AI capabilities including generative AI (Microsoft 365 Copilot), predictive analytics, and anomaly detection for clinical trial optimization.

Differentiator

Problem solved

Functional benefit

Brands

• Voicebook（患者参画支援）: 患者参画支援サービス（PPI：患者・市民参画）
• QualityLead
• zenflow
• SWIFTeS
• Vigilia
• EXSUS
• easyPRO
• コンサポ

Products and services

• QualityLead

Quantifiable outcome

• First in Japan to obtain Medidata's myMedidata eCOA Accreditation
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration15 records

AI capability12 records

Feature12 records

Partnerships

14 partnerships are on record, tiered core and strategic.

• ArisGlobalcoreTechnology or IntegrationProvides multi-tenant safety database based on LifeSphere MultiVigilance platform, enabling advanced pharmacovigilance operations
• Medidata (Dassault Systèmes)coreTechnology or IntegrationFirst in Japan to obtain myMedidata eCOA Accreditation. Strong partnership in DCT solutions, eConsent, and clinical trial technology. Achieved #1 satisfaction ranking at Medidata NEXT TOKYO 2025
• CluePointscoreTechnology or IntegrationFirst domestic CRO to introduce CluePoints' Risk-Based Quality Management solution for RBQM implementation
• Veeva SystemscoreTechnology or IntegrationPartnership for Vault EDC implementation. Collaboration on trial master file (TMF) solutions and document management
• AWS (Amazon Web Services)coreTechnology or Integrationzenflow safety information management solution achieved AWS certified software status. Joint presentations on AI×RWD technology. Active collaboration on cloud-based clinical trial solutions
• ExaMDstrategicStrategic or Co-development PartnerPartnership to build new clinical development support system for next-generation diagnostic SaMD (Software as a Medical Device) commercialization
• Frontage LaboratoriesstrategicStrategic or Co-development PartnerCollaboration to address drug lag and drug loss issues in Japan through joint clinical development support
• Omron HealthcarestrategicStrategic or Co-development PartnerBusiness partnership for promoting virtual trials using home digital devices. Joint webinars on clinical trial utilization of home digital devices
• MICINstrategicStrategic or Co-development PartnerBusiness partnership for promoting virtual trials using online diagnosis and telemedicine solutions
• HeltestrategicStrategic or Co-development PartnerCapital investment and business partnership for healthcare service development using voice data. Collaboration on voice data healthcare services
• Kumamoto UniversitystrategicStrategic or Co-development PartnerJoint provision of new solutions for drug formulation and packaging in clinical development
• NTT DatastrategicStrategic or Co-development PartnerCollaboration to promote utilization of electronic medical record data through EPNextS subsidiary
• 4G ClinicalcoreTechnology or IntegrationSelected as IRT/RTSM vendor for international clinical trials, providing randomization and trial supply management solutions
• SAS Institute JapancoreTechnology or IntegrationLong-standing partnership for SAS statistical software. Joint seminars, user groups, and co-sponsored events. Multiple collaborative presentations and excellence awards at SAS User General Meetings

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• IQVIA Holdings: Global CRO and RWE leader with significant Japan presence. Competes with EPS for multinational pharma trials run in Japan and offers overlapping capabilities in clinical operations, data management, and real-world evidence.
• Medpace Holdings: Mid-sized global CRO with growing Asia-Pacific presence. Competes with EPS on full-service Phase I-IV clinical development for emerging biotech and mid-cap pharma sponsors.
• ICON plc: Global full-service CRO with strong Asia-Pacific operations. Competes with EPS for clinical monitoring, biostatistics, and regulatory work on multi-region trials involving Japanese sites.
• Labcorp Drug Development (Fortrea): Large global CRO (spun off from Labcorp in 2023) competing for full-service clinical development contracts in Japan, including central lab and bioanalytical services overlapping with EPS's QualityLead/EXSUS offerings.
• Parexel International: Global mid-tier CRO with established Japan operations. Directly competes with EPS on clinical trial execution, biostatistics, and pharmacovigilance services for Japanese and multinational pharma.

Direct peers

• CMIC Holdings: Japan's largest domestic CRO and CDMO with comprehensive clinical development, PMS, and pharma services. Most direct Japan-based competitor to EPS across the same pharma/medical device/regenerative medicine sponsor base.
• Shin Nippon Biomedical Laboratories (SNBL): Japan-based CRO offering clinical development, bioanalysis, and translational sciences. Comparable to EPS in serving Japanese pharma with a mix of clinical and laboratory services.
• A2 Healthcare: Japanese CRO specializing in clinical trial monitoring, data management, and biostatistics. Direct competitor to EPS for Japanese pharma and medical device sponsor contracts.
• Asklep (アスクレップ): Japanese CRO providing clinical trial support, PMS, and pharmacovigilance services. Direct Japan-domestic competitor to EPS across the same pharma sponsor base.

Others

• Medidata Solutions (Dassault Systèmes): Clinical trial technology platform vendor and key partner of EPS. Listed as a peer because Medidata's eCOA, EDC, and DCT platforms overlap with EPS's proprietary IT tools (zenflow, Vigilia, easyPRO) and compete for the same technology budget allocations at pharma sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CAC Croit Corporation